Massimo Di Maio, PhD, University of Turin, Turin, Italy, discusses what we have learnt from the results from the URO-12 study about the use of PARP inhibitors as maintenance therapy for patients with advanced urothelial carcinoma. Prof. Di Maio also discusses the ATLANTIS trial, and how selection of patients for PARP inhibitor maintenance therapy based on molecular profiling could result in better outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

свернуть